# HBG1

## Overview
The HBG1 gene encodes the hemoglobin subunit gamma 1, a critical component of fetal hemoglobin (HbF), which plays a vital role in oxygen transport during fetal development. This gene is located on chromosome 11 and is part of the beta-globin gene cluster. The protein product of HBG1, the gamma 1 globin, forms a tetrameric complex with alpha globin chains, facilitating efficient oxygen delivery from the maternal to the fetal circulation. The expression of HBG1 is tightly regulated and predominantly active during fetal life, with a significant decrease postnatally as the body transitions to adult hemoglobin (HbA) production. This transition is crucial for adapting to the oxygen transport needs after birth. The regulation of HBG1 involves complex genetic and epigenetic mechanisms, including transcriptional repressors such as BCL11A, which modulate its expression to ensure proper hemoglobin switching (Han2023Base; Métais2019Genome). Understanding the function and regulation of HBG1 is essential, particularly in the context of hemoglobinopathies like sickle cell disease and beta-thalassemia, where therapeutic strategies aim to reactivate fetal hemoglobin production to alleviate disease symptoms (StarlardDavenport2022Targeting).

## Structure
The HBG1 gene encodes the gamma 1 subunit of fetal hemoglobin (HbF), which is composed of two alpha and two gamma chains. The primary structure of the HBG1 protein is a sequence of amino acids that form the gamma chain. The secondary structure includes alpha helices, which contribute to the protein's stability and function. The tertiary structure involves the folding of the gamma chain into a globular form, allowing it to interact effectively with other hemoglobin subunits. The quaternary structure of HbF is characterized by the assembly of two gamma chains with two alpha chains, forming a tetrameric protein complex that is crucial for oxygen transport in the fetus (Han2023Base; Métais2019Genome).

Post-translational modifications of the HBG1 protein may include phosphorylation and glycosylation, which can influence the protein's function and stability. These modifications are important for the regulation of hemoglobin activity and its interaction with other cellular components (Han2023Base). The HBG1 gene does not have known splice variant isoforms that significantly alter its function in fetal hemoglobin production. The structural integrity and proper assembly of the HBG1 protein are essential for its role in fetal development and oxygen delivery.

## Function
The HBG1 gene encodes the gamma globin protein, which is a crucial component of fetal hemoglobin (HbF). During fetal development, HbF is the predominant form of hemoglobin, facilitating efficient oxygen transport from the mother to the fetus. The gamma globin protein forms part of the hemoglobin tetramer, consisting of two alpha and two gamma chains, which is primarily active in erythroid cells (Métais2019Genome). 

In healthy human cells, the expression of gamma globin is tightly regulated and typically decreases after birth as the production of beta globin increases, leading to the transition from fetal hemoglobin (HbF) to adult hemoglobin (HbA) (Han2023Base). This switch is part of the natural hemoglobin switching process, where the gamma globin chains are replaced by beta globin chains, resulting in the formation of adult hemoglobin, which is more suited for oxygen transport in postnatal life (StarlardDavenport2022Targeting).

The regulation of HBG1 expression involves various genetic and epigenetic factors, including transcriptional repressors like BCL11A, which bind to the HBG1 promoter region to silence its expression after birth (Han2023Base). This regulatory mechanism ensures the proper transition from fetal to adult hemoglobin, which is essential for normal oxygen transport and overall organismal health.

## Clinical Significance
Mutations or alterations in the expression of the HBG1 gene, which encodes for the gamma subunit of fetal hemoglobin (HbF), are clinically significant in the context of hemoglobinopathies such as sickle cell disease (SCD) and beta-thalassemia. These conditions are characterized by mutations in the HBB gene, leading to defective adult hemoglobin. However, increased levels of HbF, which includes the gamma subunit encoded by HBG1, can ameliorate the symptoms of these disorders by inhibiting the polymerization of sickle hemoglobin (HbS) and improving oxygen transport (StarlardDavenport2022Targeting; Métais2019Genome).

Therapeutic strategies targeting HBG1 aim to increase HbF levels. Genome editing techniques, such as CRISPR-Cas9, have been employed to disrupt regulatory elements that repress HBG1 expression, specifically targeting the BCL11A-binding site in the HBG1 promoter. This disruption leads to increased HbF production without adverse effects on hematopoiesis or off-target mutations, offering a potential universal treatment for various beta-hemoglobinopathy mutations (Métais2019Genome).

Additionally, genetic polymorphisms in the HBG1-HBD intergenic region have been associated with variations in HbF levels, influencing the clinical severity of SCD and beta-thalassemia (Hu2020Association).

## Interactions
HBG1, the gene encoding the gamma 1 subunit of fetal hemoglobin, participates in several interactions with other proteins and nucleic acids. Molecular docking studies have shown that HBG1 forms stable complexes with the HBD and MASP1 proteins. The binding score of HBG1 to HBD was -240.26 kcal/mol, with binding sites including residues such as THR-135, GLN-127, and ASN-108. For MASP1, the binding score was -256.39 kcal/mol, with binding sites including ARG-144 and TYR-35. These interactions involve salt bridges, hydrogen bonds, and hydrophobic interactions, contributing to the stability of the protein complexes (Yang2022Beneficial).

HBG1 is also involved in a protein-protein interaction network where it is identified as a hub gene, indicating a central role in interactions related to blood coagulation, immune response regulation, and oxygen transport. This network analysis suggests that HBG1 interacts with other proteins involved in these biological processes (Yang2022Beneficial).

Additionally, the regulation of HBG1 expression is influenced by transcription factors and regulatory proteins. The GATA-1/FOG-1/NuRD pathway is involved in the repression of γ-globin expression, with FOG-1 and NuRD components playing roles in this regulatory mechanism (Miccio2010Role).


## References


[1. (Yang2022Beneficial) Chenguang Yang, Xiang Wang, Ying Guo, Xuyang Meng, Yi Li, Chenxi Xia, Lingbing Meng, Min Dong, and Fang Wang. Beneficial effect of edoxaban on preventing atrial fibrillation and coagulation by reducing inflammation via hbg1/hbd biomarkers. Frontiers in Pharmacology, June 2022. URL: http://dx.doi.org/10.3389/fphar.2022.904317, doi:10.3389/fphar.2022.904317. This article has 5 citations and is from a peer-reviewed journal.](https://doi.org/10.3389/fphar.2022.904317)

[2. (Hu2020Association) Li Hu, Ling Huang, Yuanyuan Han, Tingting Jin, Juan Liu, Minmin Jiang, Xingmei Liu, Yuanyuan Li, Wenping Han, Bangquan An, and Shengwen Huang. Association of polymorphisms in the hbg1‐hbd intergenic region with hbf levels. Journal of Clinical Laboratory Analysis, February 2020. URL: http://dx.doi.org/10.1002/jcla.23243, doi:10.1002/jcla.23243. This article has 1 citations and is from a peer-reviewed journal.](https://doi.org/10.1002/jcla.23243)

[3. (Métais2019Genome) Jean-Yves Métais, Phillip A. Doerfler, Thiyagaraj Mayuranathan, Daniel E. Bauer, Stephanie C. Fowler, Matthew M. Hsieh, Varun Katta, Sagar Keriwala, Cicera R. Lazzarotto, Kevin Luk, Michael D. Neel, S. Scott Perry, Samuel T. Peters, Shaina N. Porter, Byoung Y. Ryu, Akshay Sharma, Devlin Shea, John F. Tisdale, Naoya Uchida, Scot A. Wolfe, Kaitly J. Woodard, Yuxuan Wu, Yu Yao, Jing Zeng, Shondra Pruett-Miller, Shengdar Q. Tsai, and Mitchell J. Weiss. Genome editing of hbg1 and hbg2 to induce fetal hemoglobin. Blood Advances, 3(21):3379–3392, November 2019. URL: http://dx.doi.org/10.1182/bloodadvances.2019000820, doi:10.1182/bloodadvances.2019000820. This article has 128 citations and is from a peer-reviewed journal.](https://doi.org/10.1182/bloodadvances.2019000820)

[4. (Han2023Base) Wenyan Han, Hou-Yuan Qiu, Shangwu Sun, Zhi-Can Fu, Guo-Quan Wang, Xiaowen Qian, Lijie Wang, Xiaowen Zhai, Jia Wei, Yichuan Wang, Yi-Lin Guo, Guo-Hua Cao, Rui-Jin Ji, Yi-Zhou Zhang, Hongxia Ma, Hongsheng Wang, Mingli Zhao, Jing Wu, Lili Bi, Qiu-Bing Chen, Zifeng Li, Ling Yu, Xiaodun Mou, Hao Yin, Li Yang, Jia Chen, Bei Yang, and Ying Zhang. Base editing of the hbg promoter induces potent fetal hemoglobin expression with no detectable off-target mutations in human hscs. Cell Stem Cell, 30(12):1624-1639.e8, December 2023. URL: http://dx.doi.org/10.1016/j.stem.2023.10.007, doi:10.1016/j.stem.2023.10.007. This article has 7 citations and is from a highest quality peer-reviewed journal.](https://doi.org/10.1016/j.stem.2023.10.007)

[5. (StarlardDavenport2022Targeting) Athena Starlard-Davenport, Qingqing Gu, and Betty S. Pace. Targeting genetic modifiers of hbg gene expression in sickle cell disease: the mirna option. Molecular Diagnosis &amp; Therapy, 26(5):497–509, May 2022. URL: http://dx.doi.org/10.1007/s40291-022-00589-z, doi:10.1007/s40291-022-00589-z. This article has 11 citations.](https://doi.org/10.1007/s40291-022-00589-z)

[6. (Miccio2010Role) Annarita Miccio and Gerd A. Blobel. Role of the gata-1/fog-1/nurd pathway in the expression of human β-like globin genes. Molecular and Cellular Biology, 30(14):3460–3470, July 2010. URL: http://dx.doi.org/10.1128/mcb.00001-10, doi:10.1128/mcb.00001-10. This article has 39 citations and is from a domain leading peer-reviewed journal.](https://doi.org/10.1128/mcb.00001-10)